Duodenum-Preserving Pancreatic Head Resection for Benign and Premalignant Tumors—a Systematic Review and Meta-analysis of Surgery-Associated Morbidity - Scorecard - MDSpire
Advertisement
Duodenum-Preserving Pancreatic Head Resection for Benign and Premalignant Tumors—a Systematic Review and Meta-analysis of Surgery-Associated Morbidity
Clinical Scorecard: Systematic Review and Meta-Analysis of Surgery-Related Morbidity Following Duodenum-Preserving Resection of the Pancreatic Head for Benign and Premalignant Tumors
At a Glance
Category
Detail
Condition
Benign and premalignant tumors of the pancreatic head including cystic neoplasms and neuroendocrine tumors
Key Mechanisms
Surgical resection techniques including duodenum-preserving pancreatic head resection (DPPHR) and pancreatoduodenectomy (PD) with focus on preserving pancreatic and duodenal tissue to reduce metabolic morbidity
Target Population
Patients with symptomatic or asymptomatic benign tumors, cystic neoplasms, and neuroendocrine neoplasms of the pancreatic head
Care Setting
High-volume pancreatic surgery centers with expertise in pancreatic resections
Key Highlights
Pancreatoduodenectomy (PD) is standard for pancreatic head tumors but associated with significant metabolic morbidity and mortality.
Duodenum-preserving pancreatic head resection (DPPHR) conserves duodenum and pancreatic tissue, resulting in lower rates of new-onset diabetes mellitus and pancreatic exocrine insufficiency (<6%).
Systematic review and meta-analysis focus on early postoperative morbidity and mortality comparing DPPHR and PD, emphasizing Clavien-Dindo grade ≥ III complications and in-hospital mortality.
Guideline-Based Recommendations
Diagnosis
Use advanced cross-sectional imaging to detect benign and premalignant pancreatic head tumors including IPMN, MCN, SPN, SCN, and PNETs.
Histological confirmation of tumor type preoperatively when feasible.
Management
Consider duodenum-preserving pancreatic head resection (DPPHR) for benign and premalignant tumors to preserve pancreatic and duodenal function.
Reserve pancreatoduodenectomy (PD) for cases where oncologic clearance or tumor characteristics necessitate more extensive resection.
Apply parenchyma-sparing techniques such as tumor enucleation or middle segment resection when appropriate.
Monitoring & Follow-up
Monitor for early postoperative complications using Clavien-Dindo classification, focusing on grade III or higher complications.
Assess endocrine and exocrine pancreatic function postoperatively to detect new-onset diabetes mellitus and pancreatic exocrine insufficiency.
Risks
Recognize that PD carries higher risks of surgery-related morbidity, hospital mortality (2–4%), and long-term metabolic dysfunction.
DPPHR is associated with lower metabolic morbidity but data on early postoperative surgical morbidity require further high-quality evidence.
Patient & Prescribing Data
Patients undergoing surgical treatment for benign and premalignant pancreatic head tumors
DPPHR offers preservation of pancreatic endocrine and exocrine function with lower rates of new-onset diabetes and exocrine insufficiency compared to PD, supporting its use in appropriate cases.
Clinical Best Practices
Perform surgery in high-volume centers with multidisciplinary expertise to optimize outcomes.
Use standardized criteria such as Clavien-Dindo classification to evaluate postoperative complications.
Select surgical technique based on tumor pathology, location, and patient factors to balance oncologic control and preservation of pancreatic function.
Employ rigorous methodological quality assessment tools (e.g., Newcastle-Ottawa Scale) when evaluating evidence to guide clinical decisions.
